Regular ArticleModulation of Human Fibroblast Activity by Selected Angiogenesis Inhibitors
References (0)
Cited by (50)
Biological Drivers of Postoperative Scarring
2015, Glaucoma: Second EditionAnti-vascular endothelial growth factor therapy in glaucoma filtration surgery
2011, American Journal of OphthalmologyCitation Excerpt :Modulators of wound healing that result in more predictable outcomes may assist the achievement of this goal. In 1994, Wong and associates reported that angiogenesis inhibitors demonstrated marked inhibitory effects on both human Tenon fibroblast proliferation and migration in vitro.2 This study was performed before the availability of the anti-VEGF monoclonal antibodies, but raised the possibility that the latter may have a role in the control of wound healing after filtering surgery.
Bleb morphology and vascularity after trabeculectomy with intravitreal ranibizumab: A pilot study
2010, American Journal of OphthalmologyCitation Excerpt :More recent attempts at replacing these agents have yielded disappointing results.18 While most interventions in this area have focused on fibroblast activities, relatively few studies have been reported that focus on angiogenesis as a potential target to augment success post filtration surgery.16,19 Anti-VEGF agents, such as bevacizumab and ranibizumab, act by modulating the neovascular drive seen in diseases such as wet age-related macular degeneration as well as neovascular glaucoma.
Long-term effects of intraoperative topical bevacizumab in sutureless scleral tunnel trabeculectomy: a prospective clinical trial
2023, International OphthalmologyOne Year Results of the Preserflo MicroShunt Implantation for Refractory Glaucoma
2023, Journal of Glaucoma